Nadofaragene firadenovec-vncg is a non-replicating, vector-based gene therapy designed to deliver the gene encoding the cytokine, interferon-alfa 2b (IFNα2b), into the bladder. Immune cells are recruited into the area of cytokine release.
The drug is indicated for the treatment of patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.